公开(公告)号：US09561280B2

公开(公告)日：2017-02-07

申请号：US14793886

申请日：2015-07-08

申请人： SENJU PHARMACEUTICAL CO., LTD.

发明人： Shuichi Nishihata ,  Wakiko Asayama ,  Suzuka Iemoto

IPC分类号： A61K31/196 ,  A61K47/18 ,  A61K31/14 ,  A61K9/08 ,  A61K47/26 ,  A61K9/00

CPC分类号： A61K47/186 ,  A61K9/0043 ,  A61K9/0046 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/14 ,  A61K31/196 ,  A61K47/18 ,  A61K47/26 ,  A61K31/195 ,  A61K2300/00

摘要： An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.

摘要翻译： 一种含有（a）溴芬酸或其盐和（b）苯扎氯铵的水性液体溴芬酸组合物，其特征在于所述组合物具有防腐功效，并且（b）苯扎氯铵的浓度高于0.0005％且低于0.005％。

公开(公告)号：US09561277B2

公开(公告)日：2017-02-07

申请号：US14502014

申请日：2014-09-30

申请人： SENJU PHARMACEUTICAL CO., LTD.

发明人： Shirou Sawa ,  Shuhei Fujita

IPC分类号： A01N37/18 ,  A61K31/165 ,  A01N37/44 ,  A61K31/24 ,  A01N37/10 ,  A61K31/19 ,  A61K47/10 ,  A61K9/00 ,  A61K31/196 ,  A61K47/34 ,  A61K47/32 ,  A61K47/02 ,  A61K47/18 ,  A61K47/14

CPC分类号： A61K47/10 ,  A61K9/0043 ,  A61K9/0048 ,  A61K31/196 ,  A61K47/02 ,  A61K47/14 ,  A61K47/183 ,  A61K47/186 ,  A61K47/32 ,  A61K47/34

摘要： An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

摘要翻译： 含有2-氨基-3-（4-溴苯甲酰基）苯乙酸或其药理学上可接受的盐或其水合物的本发明的含水液体制剂，烷基芳基聚醚醇型聚合物如泰洛沙夫或聚乙二醇脂肪酸酯 如聚乙二醇单硬脂酸酯是稳定的。 由于即使在将防腐剂并入所述水性液体制剂的情况下，防腐剂长期存在足够的防腐效果，所以滴眼剂形式的水性液体制剂可用于治疗睑炎，结膜炎，巩膜炎 ，术后炎症。 此外，本发明的鼻滴形式的水性液体制剂可用于治疗过敏性鼻炎和炎症性鼻炎（例如慢性鼻炎，肥大性鼻炎，鼻息肉等）。

公开(公告)号：US20160296505A1

公开(公告)日：2016-10-13

申请号：US15031183

申请日：2014-10-30

申请人： KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION ,  THE DOSHISHA ,  SENJU PHARMACEUTICAL CO., LTD.

发明人： Noriko KOIZUMI ,  Naoki OKUMURA ,  Shigeru KINOSHITA

IPC分类号： A61K31/4439 ,  A61K31/4709 ,  A61K39/395 ,  A61K9/00 ,  A61K31/444 ,  C07K16/22

CPC分类号： A61K31/4439 ,  A61K9/0048 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/519 ,  A61K31/713 ,  A61K38/00 ,  A61K39/3955 ,  C07K16/22

摘要： The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGFβ-signal inhibitor. As a preferred TGFβ-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.

摘要翻译： 本发明提供了与内质网（ER）应激相关的疾病，病症或病症的治疗药物或预防药物。 具体地说，本发明提供了一种治疗药物或预防药物，用于与角膜上皮细胞内内质网（ER）应激相关的疾病，病症或病症，含有TGFβ信号抑制剂的药物。 作为优选的TGFβ信号抑制剂，该药物含有4- [4-（1,3-苯并间二氧杂环戊烯-5-基）-5-（2-吡啶基）-1H-咪唑-2-基]苯甲酰胺。

公开(公告)号：US09463185B2

公开(公告)日：2016-10-11

申请号：US14317145

申请日：2014-06-27

申请人： Nippon Chemiphar Co., Ltd. ,  SENJU PHARMACEUTICAL CO., LTD.

发明人： Yoshikuni Nakamura ,  Ikuko Hanano ,  Jun Inoue

IPC分类号： A61K31/421 ,  A61K31/427 ,  A61K31/426 ,  C07D263/32 ,  C07D277/24 ,  C07D417/06

CPC分类号： A61K31/427 ,  A61K31/421 ,  A61K31/426 ,  C07D263/32 ,  C07D277/24 ,  C07D417/06

摘要： A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.

摘要翻译： 含有[3- [2- [4-异丙基-2-（4-三氟甲基）苯基-5-噻唑基]乙基] -5-甲基-1,2-苯并异恶唑-6-基]氧基乙酸[4- [3- [2-（4-三氟甲基）苯基-4-异丙基-5-噻唑基]丙酰] -2-甲基苯氧基]乙酸或[4- [3- [2-（2-羟基-4-氯苯基） 5-异丙基-4-恶唑基]丙酰基] -2-甲基苯氧基]乙酸或其药理学上可接受的盐作为活性成分用作促进睑板腺上皮细胞或角膜上皮细胞增殖的试剂，以及 诸如睑板腺功能障碍，干眼症等眼部疾病的治疗剂。

公开(公告)号：US20160208250A1

公开(公告)日：2016-07-21

申请号：US14914962

申请日：2014-08-27

申请人： SENJU PHARMACEUTICAL CO., LTD.

发明人： Ayumi NAKAGAWA ,  Takeshi NAKAJIMA ,  Mitsuyoshi AZUMA

IPC分类号： C12N15/113 ,  C12N5/079

CPC分类号： C12N15/113 ,  C12N5/0621 ,  C12N2310/113 ,  C12N2310/3231 ,  C12N2320/30 ,  C12N2501/65 ,  C12N2310/321 ,  C12N2310/3521

摘要： A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided. The present inventors have also found that not only the above effects are exhibited by inhibiting miRNA richly contained in tears, but also the agent specifically acts on eye surfaces, so that the present invention can be expected to show high safety.

摘要翻译： 用于角膜上皮病症的治疗剂，其含有miR-203抑制剂; 用于促进角膜上皮细胞增殖的试剂，其含有miR-203抑制剂; 用于制造含有miR-203抑制剂的角膜上皮片的液体培养基; 以及角膜上皮片的制造方法，包括使用含有miR-203抑制剂的液体培养基培养角膜上皮细胞的步骤。 根据本发明，用于角膜上皮疾病的治疗剂，角膜上皮细胞增殖剂，用于制造角膜上皮片的液体培养基，角膜上皮片的制造方法，包括 可以提供使用液体培养基培养角膜上皮细胞的步骤和治疗角膜上皮病的方法。 本发明人还发现，通过抑制泪液中富含的miRNA，不但能够显示上述效果，而且具体地作用在眼表面上，从而可以期待本发明的安全性高。

公开(公告)号：US08940318B2

公开(公告)日：2015-01-27

申请号：US13202547

申请日：2010-01-15

申请人： Takao Sato ,  Toru Matsunaga ,  Aya Ichinokawa ,  Osamu Sakai

发明人： Takao Sato ,  Toru Matsunaga ,  Aya Ichinokawa ,  Osamu Sakai

IPC分类号： A61K9/00 ,  A61F2/00 ,  A61K9/14 ,  A61K31/21 ,  G02B1/04 ,  G02C7/04 ,  A61F9/00

CPC分类号： G02B1/043 ,  A61F9/0017 ,  A61K9/0048 ,  G02C7/04 ,  Y10S514/912

摘要： Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer, wherein the component ratio of the ionic monomers is 5 to 20 mol % inclusive relative to the total amount of monomers that constitute the gel, and the content of the anionic monomer is 15 to 25 mol % inclusive relative to the content of the cationic monomer.

摘要翻译： 公开了持续释放药物的水凝胶隐形眼镜，其能够以轻度刺激和有效的方式持续释放阴离子药物如过敏治疗剂，同时实现视力矫正。 具体公开了包含由至少阳离子单体和阴离子单体组成的离子单体的水凝胶，其中离子单体的组分比例相对于构成凝胶的单体的总量为5〜20摩尔％，含量 的阴离子单体相对于阳离子单体的含量为15〜25摩尔％。

公开(公告)号：US20140142183A1

公开(公告)日：2014-05-22

申请号：US14165976

申请日：2014-01-28

申请人： SENJU PHARMACEUTICAL CO., LTD.

发明人： Shirou SAWA ,  Shuhei FUJITA

IPC分类号： A61K31/196 ,  A61K9/00 ,  A61K47/34

CPC分类号： A61K47/10 ,  A61K9/0043 ,  A61K9/0048 ,  A61K31/196 ,  A61K47/02 ,  A61K47/14 ,  A61K47/183 ,  A61K47/186 ,  A61K47/32 ,  A61K47/34

摘要： An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).

公开(公告)号：US08518412B2

公开(公告)日：2013-08-27

申请号：US13496437

申请日：2010-09-16

申请人： Takeshi Nakajima ,  Tomoko Nakajima ,  Mitsuyoshi Azuma

发明人： Takeshi Nakajima ,  Tomoko Nakajima ,  Mitsuyoshi Azuma

IPC分类号： A61K38/18 ,  C07K14/435 ,  C07K14/475

CPC分类号： A61K9/08 ,  A61K9/0048 ,  A61K38/00 ,  C07K14/475

摘要： The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

摘要翻译： 本发明提供含有氨基酸序列的多肽，其是泪蛋白的特定部分序列，其特征在于N-末端谷氨酰胺的陀螺修饰。 多肽促进细胞和细胞外基质之间的粘附，并且在水溶液中是稳定的。

公开(公告)号：US20120245102A1

公开(公告)日：2012-09-27

申请号：US13496437

申请日：2010-09-16

申请人： Takeshi Nakajima ,  Tomoko Nakajima ,  Mitsuyoshi Azuma

发明人： Takeshi Nakajima ,  Tomoko Nakajima ,  Mitsuyoshi Azuma

IPC分类号： A61K38/17 ,  C12N5/071 ,  A61P27/02 ,  C07K14/47

CPC分类号： A61K9/08 ,  A61K9/0048 ,  A61K38/00 ,  C07K14/475

摘要： The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

摘要翻译： 本发明提供含有氨基酸序列的多肽，其是泪蛋白的特定部分序列，其特征在于N-末端谷氨酰胺的陀螺修饰。 多肽促进细胞和细胞外基质之间的粘附，并且在水溶液中是稳定的。

公开(公告)号：US20120184552A1

公开(公告)日：2012-07-19

申请号：US13496419

申请日：2010-09-17

申请人： Tomoko Nakajima ,  Wakiko Asayama ,  Tetsuya Tajika

发明人： Tomoko Nakajima ,  Wakiko Asayama ,  Tetsuya Tajika

IPC分类号： A61K31/216 ,  A61P27/06 ,  A61K31/5377

CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/5377 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/26 ,  A61K47/44 ,  A61K2300/00

摘要： The invention provides an aqueous eye drop containing latanoprost, a surfactant, and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof. In addition, the invention provides a method of suppressing adsorption of latanoprost to a resin in an aqueous solution, by adding a surfactant and an aliphatic mono- or di-carboxylic acid having a carbon number of 3-10 or a salt thereof.

摘要翻译： 本发明提供含有拉坦前列素，表面活性剂和碳数为3-10的脂肪族单羧酸或二羧酸的水性滴眼剂或其盐。 此外，本发明提供了通过加入表面活性剂和碳数为3-10的脂肪族单羧酸或二羧酸或其盐，抑制拉坦前列素对水溶液中树脂的吸附的方法。